C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | ||
| Net Income | -34,099 | -24,076 |
| Depreciation Amortization | 1,929 | 1,173 |
| Accounts receivable | N/A | 83,846 |
| Accounts payable and accrued liabilities | N/A | 3,071 |
| Other Working Capital | 84,982 | 87,049 |
| Other Operating Activity | 2,802 | -85,145 |
| Operating Cash Flow | $55,614 | $65,918 |
| Cash Flows From Investing Activities | ||
| PPE Investments | -1,286 | -1,422 |
| Other Investing Activity | -334 | 0 |
| Investing Cash Flow | $-1,620 | $-1,422 |
| Cash Flows From Financing Activities | ||
| Common Stock Issued | N/A | 206 |
| Common Stock Repurchased | N/A | -40 |
| Other Financing Activity | 244 | 0 |
| Financing Cash Flow | $244 | $166 |
| Beginning Cash Position | 38,888 | 38,888 |
| End Cash Position | 93,126 | 103,550 |
| Net Cash Flow | $54,238 | $64,662 |
| Free Cash Flow | ||
| Operating Cash Flow | 55,614 | 65,918 |
| Capital Expenditure | N/A | -1,422 |
| Free Cash Flow | 55,614 | 64,496 |